关键词: 利奈唑胺, 革兰氏阳性球菌, 耐药性, 新生儿败血症

Abstract: Objective To evaluate the clinical efficacy and safety of linezolid in the treatment of drug-resistant gram-positive coccobacterial sepsis of newborn. Methods Totally 30 neonates with drug-resistant gram-positive coccobacterial sepsis were enrolled.Clinical characteristics,pathogens,efficacy and safety of linezolid were evaluated. Results 30 resistant gram-positive strains were detected.Of these,there were 22 strains methicillin resistant coagulase negative staphylococci (MRCNS),5 strains enterococcus faecom and 3 strains staphylococcus aureus.Drug sensitivity results showed that all strains were resistant to penicillin,erythromycin,ampicillin and cefazoline,but were sensitive to linezolid.Among the MRCNS,staphylococcus epidermidis accounted for 12 strains,staphylococcus haemolyticus 6 strains,staphylococcus hominis 2 strains and staptococcus cohnii 2 strains.The clinical cure rate,significant rate,improvement rate and none effective rate were 73.3%,16.7%,6.7% and 3.3%,respectively.The overall effective rate was 90%.Overall pathogen eradication rate was 96.7%.The main adverse reactions included anemia in 2 cases,diarrhea in 2 cases (diarrhea plus granulocytopenia in 1 case),and nausea in 1 case.Liver and renal function showed no influence. Conclusion Linezolid is well-tolerated and effective in the treatment of drug-resistant gram-positive coccobacterial sepsis in neonates.

Key words: linezolid, gram-positive bacterial, drug resistance, neonatal sepsis